Announced Tue, 26 May · 19:07 IST

Audited Financial Result for quarter and year ended 31 March, 2026.

Pat NegativeEmphasis Of MatterRelated Party TransactionsEbitda Margin CompressionResults View source PDF

JHS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.9%1-day move
₹9.08
prior close
₹9.52
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1-0.2-0.8-1.8-0.9-2.6-3.6-2.4-7.6-13.0-10.0-18.0-19.2
Up moveDown movePending
AI summary

JHS Svendgaard Laboratories reported FY26 revenue of Rs 10,169.47 lakhs, up 10.5% from Rs 9,199.73 lakhs in FY25. The company reduced its net loss significantly to Rs 191.73 lakhs from Rs 1,973.84 lakhs in FY25, showing operational improvement. Q4 FY26 saw revenue of Rs 3,269.57 lakhs but a net loss of Rs 356.56 lakhs. The auditors issued an unmodified opinion but drew attention to Rs 4,190.82 lakhs in capital advances for manufacturing facilities in Himachal Pradesh and a Jammu & Kashmir project, which management considers recoverable. The company provided a Rs 500 lakh corporate guarantee to its subsidiary JHS Svendgaard Retail Venture Limited. Auditors also flagged weaknesses in internal controls over trade receivables/payables reconciliation, inventory monitoring, and TDS tracking.

Likely market impact

The company is still loss-making but has substantially narrowed losses compared to the previous year. The large capital advances and internal control weaknesses may concern investors, though the clean audit opinion and improving revenue trajectory are positives.